Reverse remodeling and prognosis of patients with heart failure with reduced ejection fraction treated with angiotensin receptor neprilysin inhibitor using cardiac magnetic resonance imaging

Reverse remodeling and prognosis of patients with heart failure with reduced ejection fraction treated with angiotensin receptor neprilysin inhibitor using cardiac magnetic resonance imaging - ARNI-LGE project

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045562

Enrollment

120

Registered

2021-09-24

Start date

2021-09-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with reduced ejection fraction

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Heart failure with left ventricular ejection fraction less than 40% Ischemic cardiomyopathy or dilated cardiomyopathy Patient starting ARNI Patient who gave written informed consent

Exclusion criteria

Exclusion criteria: Severely impaired renal function (eGFR less than 30 mL/min/1.73m2) Etiology other than ischemic cardiomyopathy and dilated cardiomyopathy

Design outcomes

Primary

Measure	Time frame
Confirmation of predictive value of reverse remodeling and prognosis using late gadolinium enhancement of cardiac MRI	—

Secondary

Measure	Time frame
Exploration of predictive factor for reverse remodeling and prognosis in patients with HFrEF treated with ARNI	—

Countries

Japan

Contacts

Public ContactKenichiro Suwa

Hamamatsu University School of Medicine Division of Cardiology

k-suwa@hama-med.ac.jp0534352267

Outcome results